IGM Biosciences
IGMS
Market cap $381M

6.40 USD

-0.11

1.69%

At close Dec 24, 4:00 PM EST

1 day

-1.69%

5 days

-14.55%

1 month

-31.91%

3 months

-62.11%

6 months

-12.33%

Year to date

-26.27%

1 year

-24.71%

5 years

-86.25%

10 years

-73.66%

About: IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Employees: 198

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,809 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

132% more capital invested

Capital invested by funds: $154M [Q2] → $357M (+$203M) [Q3]

39% more call options, than puts

Call options by funds: $1.2M | Put options by funds: $863K

0% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 24

2.99% less ownership

Funds ownership: 66.51% [Q2] → 63.52% (-2.99%) [Q3]

12% less funds holding

Funds holding: 82 [Q2] → 72 (-10) [Q3]

48% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 21

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$9

41%

upside

Avg. target

$18.71

192%

upside

High target

$27

322%

upside

7 analyst ratings

5 positive

71%

1 neutral

14%

1 negative

14%

BMO Capital Etzer Darout 29% 1-year accuracy 12 / 41 met price target	228%upside $21	Outperform Initiated	6 Dec 2024
Stifel Stephen Willey 50% 1-year accuracy 8 / 16 met price target	322%upside $27	Buy Maintained	11 Nov 2024
RBC Capital Brian Abrahams 14% 1-year accuracy 11 / 79 met price target	213%upside $20	Outperform Maintained	18 Oct 2024
Guggenheim	213%upside $20	Buy Maintained	1 Oct 2024
Wedbush Robert Driscoll 18% 1-year accuracy 12 / 65 met price target	244%upside $22	Outperform Maintained	1 Oct 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.04 per share a year ago.

IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 –

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences to Present at Three Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences:

IGM Biosciences to Present at Three Upcoming Investor Conferences

IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay

IGM Biosciences Inc.'s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company's pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower their ratings.

IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay

IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

On Tuesday, IGM Biosciences Inc. IGMS announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for autoimmune diseases.

IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

Investors Business Daily

Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite Makeover

IGM stock crashed Tuesday after the biotech company scrapped development of a cancer drug and announced three of its executives stepped down.

Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite Makeover

IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases

The biotechnology company says it will focus only on autoimmune diseases.

IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases

IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Tuesday.

IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus –

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

Zacks Investment Research

IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?

IGM Biosciences (IGMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?

See News Rankings

Charts implemented using Lightweight Charts™